1.Lake AA. Neighbourhood food environments: food choice, foodscapes and planning for health. Proc Nutr Soc 2018;77: 239–246.
2.Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. Br J Nutr 2012;108: 1915–1923.
3.Mutt SJ, Hyppönen E, Saarnio J, Järvelin MR, Herzig KH. Vitamin D and adipose tissue—more than storage. Front Physiol 2014;5.
4.Mai XM, Chen Y, Camargo CA, Jr., Langhammer A. Cross-sectional and prospective cohort study of serum 25-hydroxyvitamin D level and obesity in adults: the HUNT study. Am J Epidemiol 2012;175: 1029–1036.
5.Nikooyeh B, Neyestani TR, Farvid M, et al. Daily consumption of vitamin D- or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial. Am J Clin Nutr 2011;93: 764–771.
6.Neyestani TR, Nikooyeh B, Alavi-Majd H, et al. Improvement of vitamin D status via daily intake of fortified yogurt drink either with or without extra calcium ameliorates systemic inflammatory biomarkers, including adipokines, in the subjects with type 2 diabetes. J Clin Endocrinol Metab 2012;97: 2005–2011.
7.Nikooyeh B, Neyestani TR, Zahedirad M, et al. Vitamin D-Fortified Bread Is as Effective as Supplement in Improving Vitamin D Status: A Randomized Clinical Trial. J Clin Endocrinol Metab 2016;101: 2511–2519.
8.Peterson CA, Belenchia AM. Vitamin D Deficiency & Childhood Obesity: A Tale of Two Epidemics. Mo Med 2014;111: 49–53.
9.Ponterio E, Gnessi L. Adenovirus 36 and Obesity: An Overview. Viruses 2015;7: 3719–3740.
10.Nam JH, Na HN, Atkinson RL, Dhurandhar NV. Genomic stability of adipogenic human adenovirus 36. Int J Obes (Lond) 2014;38: 321–324.
11.Sohrab SS, Kamal MA, Atkinson RL, Alawi MM, Azhar EI. Viral Infection and Obesity: Current Status and Future Prospective. Curr Drug Metab 2017;18: 798–807.
12.Karamese M, Altoparlak U, Turgut A, Aydogdu S, Karamese SA. The relationship between adenovirus–36 seropositivity, obesity and metabolic profile in Turkish children and adults. Epidemiol Infect 2015;143: 3550–3556.
13.Kocazeybek B, Dinc HO, Ergin S, et al. Evaluation of Adenovirus–36 (Ad–36) antibody seropositivity and adipokine levels in obese children. Microb Pathog 2017;108: 27–31.
14.Park S, Kim J, Shin HJ, et al. Tracking Study About Adenovirus 36 Infection: Increase of Adiposity. J Microbiol Biotechnol 2015;25: 2169–2172.
15.Lin WY, Dubuisson O, Rubicz R, et al. Long-term changes in adiposity and glycemic control are associated with past adenovirus infection. Diabetes Care 2013;36: 701–707.
16.Shang Q, Wang H, Song Y, et al. Serological data analyses show that adenovirus 36 infection is associated with obesity: a meta-analysis involving 5739 subjects. Obesity (Silver Spring) 2014;22: 895–900.
17.Yamada T, Hara K, Kadowaki T. Association of adenovirus 36 infection with obesity and metabolic markers in humans: a meta-analysis of observational studies. PLoS One 2012;7: e42031.
18.Almgren M, Atkinson R, He J, et al. Adenovirus–36 is associated with obesity in children and adults in Sweden as determined by rapid ELISA. PLoS One 2012;7: e41652.
19.Berger PK, Pollock NK, Laing EM, et al. Association of adenovirus 36 infection with adiposity and inflammatory-related markers in children. J Clin Endocrinol Metab 2014;99: 3240–3246.
20.Broderick M, Hansen C, Irvine M, et al. Adenovirus 36 seropositivity is strongly associated with race and gender, but not obesity, among US military personnel. International journal of obesity 2010;34: 302.
21.Ehsandar S, Zarkesh M, Daneshpour M, Bandehpour M, Azizi F, Hedayati M. [Prevalence of Human Adenovirus 36 and Its Association with Overweight/Obese and Lipid Profiles in the Tehran Lipid and Glucose Study]. Iranian J Endocrinol Metab 2014;16: 88–94.
22.Xu MY, Cao B, Wang DF, et al. Human Adenovirus 36 Infection Increased the Risk of Obesity: A Meta-Analysis Update. Medicine (Baltimore) 2015;94: e2357.
23.Whigham LD, Israel BA, Atkinson RL. Adipogenic potential of multiple human adenoviruses in vivo and in vitro in animals. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2006;290: R190-R194.
24.Atkinson RL. Human adenovirus–36 and childhood obesity. Int J Pediatr Obes 2011;6 Suppl 1: 2–6.
25.Aldhoon-Hainerova I, Zamrazilova H, Atkinson RL, et al. Clinical and laboratory characteristics of 1179 Czech adolescents evaluated for antibodies to human adenovirus 36. Int J Obes (Lond) 2014;38: 285–291.
26.Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2014;384: 766–781.
27.Hwang KA, Park S, Ahn JH, Nam JH. Development of a standard protocol for quantitative polymerase chain reaction to detect adenovirus 36, which is associated with obesity. Acta Virol 2018;62: 350–359.
28.Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet 2016;387: 1377–1396.
29.Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC public health 2009;9: 88.
30.Collaboration PS. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. The Lancet 2009;373: 1083–1096.
31.Almgren M, Atkinson RL, Hilding A, et al. Human adenovirus–36 is uncommon in type 2 diabetes and is associated with increased insulin sensitivity in adults in Sweden. Ann Med 2014;46: 539–546.
32.Dhurandhar NV, Geurts L, Atkinson RL, et al. Harnessing the beneficial properties of adipogenic microbes for improving human health. Obes Rev 2013;14: 721–735.
33.Sabin MA, Burgner D, Atkinson RL, et al. Longitudinal investigation of adenovirus 36 seropositivity and human obesity: the Cardiovascular Risk in Young Finns Study. Int J Obes (Lond) 2015;39: 1644–1650.
34.Nikooyeh B, Abdollahi Z, Hajifaraji M, et al. Vitamin D status and cardiometabolic risk factors across latitudinal gradient in Iranian adults: National food and nutrition surveillance. Nutr Health 2017;23: 87–94.
35.Katzmarzyk PT, Barreira TV, Broyles ST, et al. Association between body mass index and body fat in 9–11-year-old children from countries spanning a range of human development. Int J Obes Suppl 2015;5: S43–46.
36.Neyestani TR, Gharavi A, Kalayi A. Determination of serum 25-hydroxy cholecalciferol using high-performance liquid chromatography: a reliable tool for assessment of vitamin D status. Int J Vitam Nutr Res 2007;77: 341–346.
37.Christoffel KK, Wang X, Binns HJ. Early origins of child obesity: bridging disciplines and phases of development—September 30—October 1, 2010. Int J Environ Res Public Health 2012;9: 1227–1262.
38.Neyestani T. Immune Alterations in Metabolic Syndrome: The Old Story of Chicken and Egg. Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases. Elsevier, 2013, pp 431–450.
39.Na HN, Hong YM, Ye MB, Park S, Kim IB, Nam JH. Adenovirus 36 attenuates weight loss from exercise but improves glycemic control by increasing mitochondrial activity in the liver. PLoS One 2014;9: e114534.
40.Nikooyeh B, Neyestani TR, Alavi-Majd H, et al. Vitamin D Deficiency is Associated with the Metabolic Syndrome in Subjects with Type 2 Diabetes. Nutr Food Sci Res 2014;1: 3–10.
41.Nikooyeh B, Neyestani TR. Oxidative stress, type 2 diabetes and vitamin D: past, present and future. Diabetes/metabolism research and reviews 2016;32: 260–267.
42.Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. Rev Med Virol 2017;27.
43.Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol 2011;50: 194–200.
44.Borella E, Nesher G, Israeli E, Shoenfeld Y. Vitamin D: a new anti-infective agent? Ann N Y Acad Sci 2014;1317: 76–83.
45.Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell 2009;138: 30–50.
46.Skrobot A, Demkow U, Wachowska M. Immunomodulatory Role of Vitamin D: A Review. 2018.
47.del Giudice MM, Indolfi C, Strisciuglio C. Vitamin D: Immunomodulatory Aspects. Journal of clinical gastroenterology 2018;52: S86-S88.
48.Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017;390: 2627–2642.
49.Na HN, Nam JH. Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36. Int J Obes (Lond) 2014;38: 1470–1474.
50.Dubuisson O, Day RS, Dhurandhar NV. Accurate identification of neutralizing antibodies to adenovirus Ad36, -a putative contributor of obesity in humans. J Diabetes Complications 2015;29: 83–87.